General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.
1. At a Glance
A 180-acre complex at Barnala in Punjab spent three months turning acetic acid into painkiller ingredients. The output went to 80 countries, and the June quarter numbers arrived with unusual volume.
Revenue from operations was ₹756.26 crore against ₹551.69 crore a year earlier. That is a rise of 37.1%. Profit after tax was ₹64.48 crore against ₹33.96 crore, up 89.9%. Operating profit came in at ₹103.55 crore against ₹62.15 crore.
Quarterly revenue had spent nine straight quarters wandering between ₹502 crore and ₹619 crore. That is the corporate equivalent of a treadmill on a gentle incline. A rise of ₹137 crore over the immediately preceding quarter is a change of pace.
Management attributed the profitability to “higher operating leverage, better capacity utilization, improved product mix, and continued focus on operational efficiencies”. That is four phrases doing the work of one. Management then took apart the obvious alternative explanation. Asked about inventory gains, management said “this quarter we are not having inventory gain”. On one-offs, management said “Nothing… no extraordinary thing.”
Non-ibuprofen products reached 43% of pharma revenue in the three months to June 2026. The same figure was 36% a year earlier. Exports were 28.5% of revenue against 24.4%. A molecule little known outside the plasticiser trade started production in May.
2. Introduction
IOL was incorporated on 29 September 1986 by Varinder Gupta and Rajinder Gupta. The plan was a plant to make acetic acid. The shares were listed on the BSE in 1991.
What followed is one of the more literal build-outs in Indian chemicals. Acetic acid came first, then ethyl acetate in 1996 and acetic anhydride in 1999. Ibuprofen production began only in 2000. The company now holds a 35% share of the world ibuprofen market.
The pattern repeats with the persistence of a firm that read one strategy book and liked it. Make the input, then make the thing that needs the input. By 2009 it was producing IBB, MCA and acetyl chloride. Those are the three raw materials ibuprofen requires. A 13 MW power plant of its own followed in 2010.
Units 01 to 11 arrived over two decades, each with a dedicated molecule. Unit-04 makes metformin and Unit-06 makes pantoprazole. Unit-11 makes paracetamol at 10,800 tonnes a year.
Recent moves have kept the rhythm. In the year to March 2026 ethyl acetate capacity was raised to 120,000 tonnes a year. Acetic anhydride went to 32,000 tonnes and pantoprazole to 276. Triacetin was installed at 6,000 tonnes a year.
IOL Pharmaxis UK Limited was incorporated in October 2025 as a wholly owned subsidiary. The auditor’s report says its operations commenced on 2 April 2026. It entered the consolidated accounts for the first time this quarter. It carried total assets of ₹0.12 crore and no revenue, which is where all subsidiaries begin.
China’s drug regulator, the NMPA, approved Clopidogrel Bisulfate as an active ingredient on 14 July 2026. Ibuprofen had cleared the same regulator in April 2025. Europe’s EDQM, which certifies ingredient quality for the region, issued four certificates over the same stretch. Minoxidil came in December 2025 and Clopidogrel Besilate in February 2026. Sitagliptin Phosphate Monohydrate and Pantoprazole Sodium Sesquihydrate Process-III both came in October 2025.
The company holds 21 such European certificates and 14 drug master files with the USFDA. A master file is the dossier describing how a molecule is made. The 39th annual general meeting is scheduled for 2 September 2026.
US
Now live
US Stocks terminal is live
13,000+ US tickers · EDGAR fundamentals · screener and filings feed — the same terminal, for American markets.
Explore →
3. Business Model: WTF Do They Even Do?
Two segments share one campus, and the supply chain mostly talks to itself.
Pharmaceuticals brought in ₹469.49 crore of segment revenue in the quarter. It makes active pharmaceutical ingredients, the drug molecule itself, before somebody else presses it into a branded tablet. The portfolio reads like a well-stocked medicine cabinet, sorted by suffering. Ibuprofen and its lysinate, sodium and dex- variants go into inflammation. Metformin goes into diabetes, paracetamol into fever and clopidogrel into blood platelets. Pantoprazole handles acid, fenofibrate cholesterol, and levetiracetam and lamotrigine epilepsy. Losartan potassium and minoxidil go into high blood pressure. Installed ingredient capacity is 30,726 tonnes a year.
Specialty Chemicals brought in ₹364.96 crore. Ethyl acetate runs at 120,000 tonnes a year and acetic anhydride at 32,000. Iso butyl benzene runs at 12,000 tonnes and mono chloro acetic acid at 7,200. Acetyl chloride runs at 5,200 tonnes and the new triacetin line at 6,000. Total installed capacity across both segments is 213,126 tonnes a year.
Here the structure gets neat. Iso butyl benzene, mono chloro acetic acid and acetyl chloride are all listed as inputs for ibuprofen. Acetic anhydride is the major input for paracetamol. So the chemicals division’s biggest customer is a building on the same road. Inter-segment
